Matches in Wikidata for { <http://www.wikidata.org/entity/Q93068554> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q93068554 description "article scientifique publié en 2019" @default.
- Q93068554 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q93068554 description "im Juni 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q93068554 description "scientific article published on 27 June 2019" @default.
- Q93068554 description "wetenschappelijk artikel" @default.
- Q93068554 description "наукова стаття, опублікована 27 червня 2019" @default.
- Q93068554 name "Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"" @default.
- Q93068554 name "Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"" @default.
- Q93068554 type Item @default.
- Q93068554 label "Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"" @default.
- Q93068554 label "Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"" @default.
- Q93068554 prefLabel "Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"" @default.
- Q93068554 prefLabel "Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"" @default.
- Q93068554 P1433 Q93068554-C4D067E4-6AD9-4B44-A5C0-F4ED9274A1F9 @default.
- Q93068554 P1476 Q93068554-3BB1F4D8-A517-477A-AED6-B78D71DB07C7 @default.
- Q93068554 P2093 Q93068554-0FA7115F-0713-48FE-A098-04C440578F72 @default.
- Q93068554 P2093 Q93068554-B3BEC75C-BF6C-4F06-9B0B-B998F03D1906 @default.
- Q93068554 P304 Q93068554-98FB3F53-1534-4B40-AF33-66FF008F7D9A @default.
- Q93068554 P31 Q93068554-219BED31-5D7F-4E7E-AF6B-30DE4CF18033 @default.
- Q93068554 P356 Q93068554-38162628-59E3-4327-8F1C-0665D8547E9D @default.
- Q93068554 P433 Q93068554-AC931861-B8A9-4D16-9C9C-F1596850A3F4 @default.
- Q93068554 P478 Q93068554-71D41F99-F4C2-4076-BF96-A2F88AF41F12 @default.
- Q93068554 P577 Q93068554-176B1C45-9364-440F-986D-6ACCF6DC4BDC @default.
- Q93068554 P698 Q93068554-9C7E78C6-6597-40AA-9262-D112FCBF3745 @default.
- Q93068554 P921 Q93068554-38EE6217-7CE5-4566-9337-DB990D9B3A33 @default.
- Q93068554 P921 Q93068554-8769CBD2-18A8-4A70-873F-7D52AB7D46A4 @default.
- Q93068554 P356 BIOM.12991 @default.
- Q93068554 P698 31245839 @default.
- Q93068554 P1433 Q2025724 @default.
- Q93068554 P1476 "Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"" @default.
- Q93068554 P2093 "Andrew G Chapple" @default.
- Q93068554 P2093 "Peter F Thall" @default.
- Q93068554 P304 "389-391" @default.
- Q93068554 P31 Q13442814 @default.
- Q93068554 P356 "10.1111/BIOM.12991" @default.
- Q93068554 P433 "2" @default.
- Q93068554 P478 "75" @default.
- Q93068554 P577 "2019-06-27T00:00:00Z" @default.
- Q93068554 P698 "31245839" @default.
- Q93068554 P921 Q42824827 @default.
- Q93068554 P921 Q5452194 @default.